Raymond James upgrades Humana to Outperform and sets $520 price target
Raymond James raised its rating on Humana Inc. (HUM) from Market Perform to Outperform, citing higher Medicare Advantage quality ratings and stronger earnings outlook. The analyst set a new price target of $520 and lifted the 2028 earnings‑per‑share estimate to $43.12. The upgrade came after Humana disclosed that 95% of its Medicare Advantage members will be in 4‑star or higher plans for 2027, up from 41% in 2026.
Why it matters
The higher rating and $520 target suggest upside potential for investors, while the raised 2028 EPS estimate signals improved profitability expectations (Raymond James note). The upgrade may also drive short‑term buying pressure as traders react to the new outlook.
Key facts
- 1Raymond James upgraded Humana to Outperform from Market Perform. investing.com
- 2The firm set a price target of $520 for Humana. investing.com
- 3Humana’s stock was trading at $431.87 at the time of the upgrade. investing.com
- 4Raymond James increased its 2028 earnings‑per‑share estimate to $43.12 from $26.68. investing.com
- 5Humana expects 95% of its Medicare Advantage members to be in 4‑star or higher plans for plan year 2027, up from 41% in 2026. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.